KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EBIT: 2009-2025

Historic EBIT for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $35.8 million.

  • Acadia Pharmaceuticals' EBIT rose 12.99% to $35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.9 million, marking a year-over-year increase of 114.66%. This contributed to the annual value of $230.8 million for FY2024, which is 414.52% up from last year.
  • Acadia Pharmaceuticals' EBIT amounted to $35.8 million in Q3 2025, which was up 10.45% from $32.4 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' EBIT ranged from a high of $153.5 million in Q4 2024 and a low of -$113.0 million during Q1 2022.
  • In the last 3 years, Acadia Pharmaceuticals' EBIT had a median value of $30.4 million in 2024 and averaged $22.3 million.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 101.73% in 2022, then surged by 902.21% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' EBIT (Quarterly) stood at -$44.7 million in 2021, then dropped by 3.15% to -$46.1 million in 2022, then surged by 175.86% to $34.9 million in 2023, then surged by 339.28% to $153.5 million in 2024, then rose by 12.99% to $35.8 million in 2025.
  • Its EBIT stands at $35.8 million for Q3 2025, versus $32.4 million for Q2 2025 and $19.3 million for Q1 2025.